FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147109610> ?p ?o ?g. }

• W2147109610 endingPage "20" @default.
• W2147109610 startingPage "512" @default.
• W2147109610 abstract "Aerosolized prostacyclin (PGI(2)) has been suggested for selective pulmonary vasodilation, but its effect rapidly levels off after termination of nebulization. Stabilization of the second-messenger cAMP by phosphodiesterase (PDE) inhibition may offer a new strategy for amplification of the vasodilative response to nebulized PGI(2). In perfused rabbit lungs, continuous infusion of the thromboxane mimetic U46619 was used to establish stable pulmonary hypertension [increase in pulmonary arterial pressure (pPA) from approximately 7 to approximately 32 mm Hg], which is accompanied by progressive edema formation and severe disturbances in gas exchange with a predominance of shunt flow (increase from <2 to approximately 58%, as assessed by the multiple inert gas elimination technique). In the absence of PGI(2), dose-effect curves for intravascular and aerosol administration of the specific PDE3 inhibitor motapizone, the PDE4 inhibitor rolipram, and the dual-selective PDE3/4 inhibitor tolafentrine on pulmonary hemodynamics were established (potency rank order: rolipram > tolafentrine approximately motapizone; highest efficacy on coapplication of rolipram and motapizone). Ten-minute aerosolization of PGI(2) was chosen to effect a moderate pPA decrease (approximately 4 mm Hg; rapidly returning to prenebulization values within 10-15 min) with only a slight reduction in shunt flow (approximately 49%). Prior application of subthreshold doses of i.v. or inhaled PDE3 or PDE4 inhibitors, which per se did not affect pulmonary hemodynamics, caused prolongation of the post-PGI(2) decrease in pPA. The most effective approach, rolipram plus motapizone, amplified the maximum pPA decrease in response to PGI(2) to approximately 9 to 10 mm Hg, prolonged the post-PGI(2) vasorelaxation to >60 min, reduced the extent of lung edema formation by 50%, and decreased the shunt flow to approximately 19% (i.v. rolipram/motapizone) and 28% (aerosolized rolipram/motapizone). We conclude that lung PDE3/4 inhibition, achieved by intravascular or transbronchial administration of subthreshold doses of specific PDE inhibitors, synergistically amplifies the pulmonary vasodilatory response to inhaled PGI(2), concomitant with an improvement in ventilation-perfusion matching and a reduction in lung edema formation. The combination of nebulized PGI(2) and PDE3/4 inhibition may thus offer a new concept for selective pulmonary vasodilation, with maintenance of gas exchange in respiratory failure and pulmonary hypertension." @default.
• W2147109610 created "2016-06-24" @default.
• W2147109610 creator A5006074947 @default.
• W2147109610 creator A5030309692 @default.
• W2147109610 creator A5030937874 @default.
• W2147109610 creator A5040574354 @default.
• W2147109610 creator A5052349036 @default.
• W2147109610 creator A5057524424 @default.
• W2147109610 creator A5067482129 @default.
• W2147109610 creator A5072954654 @default.
• W2147109610 creator A5090575691 @default.
• W2147109610 date "2000-02-01" @default.
• W2147109610 modified "2023-09-23" @default.
• W2147109610 title "Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange." @default.
• W2147109610 cites W1484918835 @default.
• W2147109610 cites W1567859570 @default.
• W2147109610 cites W1787652680 @default.
• W2147109610 cites W1839628631 @default.
• W2147109610 cites W1923670619 @default.
• W2147109610 cites W1927797304 @default.
• W2147109610 cites W1932677443 @default.
• W2147109610 cites W1933885105 @default.
• W2147109610 cites W1970872524 @default.
• W2147109610 cites W1973519389 @default.
• W2147109610 cites W1985648680 @default.
• W2147109610 cites W1990005133 @default.
• W2147109610 cites W1990856809 @default.
• W2147109610 cites W1994226794 @default.
• W2147109610 cites W1994320298 @default.
• W2147109610 cites W2003922574 @default.
• W2147109610 cites W2007398897 @default.
• W2147109610 cites W2020712411 @default.
• W2147109610 cites W2021061253 @default.
• W2147109610 cites W2026475877 @default.
• W2147109610 cites W2041789894 @default.
• W2147109610 cites W2042322531 @default.
• W2147109610 cites W2046185343 @default.
• W2147109610 cites W2052748149 @default.
• W2147109610 cites W2057175513 @default.
• W2147109610 cites W2078849046 @default.
• W2147109610 cites W2087825562 @default.
• W2147109610 cites W2093216413 @default.
• W2147109610 cites W2093710294 @default.
• W2147109610 cites W2107659546 @default.
• W2147109610 cites W2113362693 @default.
• W2147109610 cites W2115511584 @default.
• W2147109610 cites W2145910657 @default.
• W2147109610 cites W2150722914 @default.
• W2147109610 cites W2165144526 @default.
• W2147109610 cites W2166389885 @default.
• W2147109610 cites W2177264898 @default.
• W2147109610 cites W2236045627 @default.
• W2147109610 cites W2413355042 @default.
• W2147109610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10640287" @default.
• W2147109610 hasPublicationYear "2000" @default.
• W2147109610 type Work @default.
• W2147109610 sameAs 2147109610 @default.
• W2147109610 citedByCount "15" @default.
• W2147109610 countsByYear W21471096102014 @default.
• W2147109610 crossrefType "journal-article" @default.
• W2147109610 hasAuthorship W2147109610A5006074947 @default.
• W2147109610 hasAuthorship W2147109610A5030309692 @default.
• W2147109610 hasAuthorship W2147109610A5030937874 @default.
• W2147109610 hasAuthorship W2147109610A5040574354 @default.
• W2147109610 hasAuthorship W2147109610A5052349036 @default.
• W2147109610 hasAuthorship W2147109610A5057524424 @default.
• W2147109610 hasAuthorship W2147109610A5067482129 @default.
• W2147109610 hasAuthorship W2147109610A5072954654 @default.
• W2147109610 hasAuthorship W2147109610A5090575691 @default.
• W2147109610 hasConcept C120770815 @default.
• W2147109610 hasConcept C126322002 @default.
• W2147109610 hasConcept C134018914 @default.
• W2147109610 hasConcept C178853913 @default.
• W2147109610 hasConcept C181199279 @default.
• W2147109610 hasConcept C185592680 @default.
• W2147109610 hasConcept C2776645727 @default.
• W2147109610 hasConcept C2776958096 @default.
• W2147109610 hasConcept C2781128415 @default.
• W2147109610 hasConcept C42219234 @default.
• W2147109610 hasConcept C55493867 @default.
• W2147109610 hasConcept C58141971 @default.
• W2147109610 hasConcept C62826618 @default.
• W2147109610 hasConcept C71924100 @default.
• W2147109610 hasConcept C98274493 @default.
• W2147109610 hasConceptScore W2147109610C120770815 @default.
• W2147109610 hasConceptScore W2147109610C126322002 @default.
• W2147109610 hasConceptScore W2147109610C134018914 @default.
• W2147109610 hasConceptScore W2147109610C178853913 @default.
• W2147109610 hasConceptScore W2147109610C181199279 @default.
• W2147109610 hasConceptScore W2147109610C185592680 @default.
• W2147109610 hasConceptScore W2147109610C2776645727 @default.
• W2147109610 hasConceptScore W2147109610C2776958096 @default.
• W2147109610 hasConceptScore W2147109610C2781128415 @default.
• W2147109610 hasConceptScore W2147109610C42219234 @default.
• W2147109610 hasConceptScore W2147109610C55493867 @default.
• W2147109610 hasConceptScore W2147109610C58141971 @default.
• W2147109610 hasConceptScore W2147109610C62826618 @default.
• W2147109610 hasConceptScore W2147109610C71924100 @default.

• next